HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on CervoMed (NASDAQ: CRVO) and maintained a price target of $25 for the company's stock.